
Ask a doctor about a prescription for PERINDOPRIL KRKA 4 mg TABLETS
Package Leaflet: Information for the Patient
Perindopril Krka 4 mg Tablets EFG
perindopril tert-butylamine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
The active substance of Perindopril Krka belongs to the group of antihypertensive medicines, angiotensin-converting enzyme inhibitors (ACE inhibitors).
Perindopril Krka is used:
Do not take Perindopril Krka
Warnings and precautions
Consult your doctor or pharmacist before starting to take Perindopril Krka.
It may not be suitable for you, or you may require regular individual monitoring. Therefore, before starting to take Perindopril Krka, inform your doctor of the following:
Your doctor may need to monitor your kidney function, blood pressure, and blood electrolyte levels (such as potassium) at regular intervals.
See also the information under the heading "Do not take Perindopril Krka".
Angioedema
In patients treated with ACE inhibitors, including Perindopril Krka, angioedema (severe allergic reaction with swelling of the face, lips, tongue, or throat with difficulty swallowing or breathing) has been reported. This can occur at any time during treatment. If you develop such symptoms, you should stop treatment with Perindopril Krka and see a doctor immediately. See also section 4.
Tell your doctor if you are planning to become pregnant or think you may be pregnant. Perindopril Krka is not recommended in the early stages of pregnancy, and should not be taken if you are more than 3 months pregnant, as it may seriously harm your baby if taken during this period (see section pregnancy).
If you develop any of the following symptoms, consult your doctor immediately:
At the start of treatment and during dose adjustment periods, it may be necessary to increase the frequency of medical check-ups. You should attend all the appointments that your doctor schedules for you, even if you feel well. Your doctor will tell you how often you should come for a check-up.
To prevent any possible complications with Perindopril Krka, you should also inform your doctor if you take Perindopril Krka:
Children and adolescents
The use of perindopril is not recommended in children and adolescents up to the age of 18.
Other medicines and Perindopril Krka
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Do not take medicines that can be obtained without a prescription without consulting your doctor first. This includes:
Tell your doctor if you are taking any of the following to make sure it is safe to take Perindopril Krka at the same time:
Your doctor may need to adjust your dose and/or take other precautions:
Taking Perindopril Krka with food, drinks, and alcohol
It is recommended to take Perindopril Krka before meals to reduce the influence of food on the way the medicine works. Drinking alcohol while taking Perindopril Krka may cause dizziness. You should consult your doctor if alcohol consumption is advisable for you while being treated with Perindopril Krka.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Tell your doctor if you are pregnant (or might be). Your doctor will advise you to stop taking Perindopril Krka before you become pregnant or as soon as you know you are pregnant and will prescribe another medicine for you instead. Perindopril Krka is not recommended in the first trimester of pregnancy, and should not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken from the third month onwards.
Breastfeeding
Tell your doctor if you are breastfeeding or about to start breastfeeding. Perindopril Krka is not recommended for mothers who are breastfeeding, and your doctor may choose another treatment for you if you want to breastfeed, especially if your baby is newborn or premature.
Driving and using machines
It is advised not to drive a car or use machines until you know how Perindopril Krka affects you. Individual reactions such as dizziness and weakness can occur in some patients, particularly at the start of treatment or in combination with other antihypertensive medication.
As a result, the ability to drive or use machines may be affected.
Perindopril Krka contains lactose monohydrate and sodium.
If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
This medicine contains less than 23 mg of sodium (1mmol) per tablet; this is, essentially, "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
The initial and maintenance dose for the treatment of arterial hypertension is usually 4 mg once a day (1 tablet of Perindopril Krka 4 mg). If necessary, after a month of treatment, the dose may be increased to 8 mg once a day (2 tablets of Perindopril Krka 4 mg).
The recommended initial dose for the treatment of symptomatic heart failure is 2 mg of perindopril (half a tablet of Perindopril Krka 4 mg or 1 tablet of Perindopril Krka 2 mg if available) once a day; this dose may be increased to 4 mg of perindopril (1 tablet of Perindopril Krka 4 mg or 2 tablets of Perindopril Krka 2 mg, if available) once a day, as needed.
The recommended initial dose for the treatment of stable coronary artery disease is 4 mg of perindopril once a day (1 tablet of Perindopril Krka 4 mg); after two weeks, the dose may be increased to 8 mg of perindopril once a day (2 tablets of Perindopril Krka 4 mg) if well tolerated.
The tablets should be swallowed with a glass of water, before breakfast, at the same time every day.
During the course of treatment, your doctor will adjust the dose according to the effects to be achieved, taking into account your therapeutic needs.
Kidney problems
If you have kidney problems, your doctor may prescribe a lower dose.
Liver problems
No dose adjustment is necessary.
Elderly patients
The recommended dose in elderly patients depends on kidney function.
Your doctor will determine the duration of your treatment based on your clinical condition.
Use in children and adolescents
The efficacy and safety of perindopril in children and adolescents under 18 years of age have not been established. Therefore, its use is not recommended in children.
If you think the action of this medicine is too weak or too strong for you, consult your doctor or pharmacist.
If you take more Perindopril Krka than you should
If you take more Perindopril Krka than you should, consult your doctor or pharmacist immediately.
The most common symptom in case of overdose is a sudden drop in blood pressure (hypotension). Other symptoms are rapid or slow heartbeat (tachy or bradycardia), unpleasant sensation of irregular heartbeat and/or strong heartbeat (palpitations), excessive frequency and depth of breathing, dizziness, anxiety, and/or cough.
If your blood pressure drops substantially, it can be treated by laying the patient down with their legs elevated and using only a small pillow to support their head.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Perindopril Krka
It is important to take this medicine every day. However, if you forget to take a dose, continue with the next dose as normal. Do not take a double dose to make up for forgotten doses. If you forget to take more than one dose, take another as soon as you remember and then continue with the treatment prescribed by your doctor.
If you stop taking Perindopril Krka
Stopping treatment with Perindopril Krka may increase blood pressure, increasing the risk of secondary complications to hypertension, especially at the cardiac, cerebral, and renal levels. In patients with heart failure, it may lead to complications that require hospitalization. Therefore, before stopping your treatment with Perindopril Krka, consult your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Stoptreatment with this medicine andgoimmediately to your doctorif you experience any of the following adverse effects that can be serious:
Adverse effects were categorized according to incidence, as follows:
Frequent(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people)
Very Rare(may affect up to 1 in 10,000 people)
Frequency Not Known(cannot be estimated from available data)
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Do not store above 30°C.
Store in the original packaging.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Perindopril Krka
Appearance of the Product and Package Contents
The tablets are white, oblong, biconvex with beveled edges and marked on one face. The tablet can be divided into equal doses.
The tablets are available in boxes of 7, 14, 28, 30, 50, 60, 90, or 100 tablets in blisters.
Only some package sizes may be marketed.
Marketing Authorization Holder:
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturer:
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA-POLSKA Sp. z o.o., ul. Równolegla 5, 02-235 Warszawa, Poland
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura 10, Pta. Baja, Oficina 1, 28108 Alcobendas, Madrid, Spain
This medicine has been authorized in the EEA Member States with the following names:
Czech Republic Prenessa 4 mg tablets
Denmark Perindopril tert-butylamin Krka 4 mg tablets
Estonia Prenessa
Finland Perindopril Krka 4 mg tablets
France Prenessa 4 mg tablets
Germany Prenessa 4 mg tablets
Latvia Prenessa 4 mg tablets
Lithuania Prenessa 4 mg tablets
Poland Prenessa 4 mg tablets
Romania Prenessa 4 mg tablets
Slovakia Prenessa 4 mg tablets
Spain Perindopril Krka 4 mg tablets
United Kingdom Perindopril 4 mg tablets
Portugal Perindopril Krka 4 mg
Date of the Last Revision of this Leaflet: November 2021
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of PERINDOPRIL KRKA 4 mg TABLETS in November, 2025 is around 5.4 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for PERINDOPRIL KRKA 4 mg TABLETS – subject to medical assessment and local rules.